Involving A Nucleic Acid Encoding A Protein Related To The Nervous System, (e.g., Nerve Related Factors, Brain-derived Cytokines, Nerve Cell Biomarker, Etc.) Patents (Class 435/6.16)
  • Patent number: 10968285
    Abstract: The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 6, 2021
    Assignee: Albert-Ludwigs Universität Freiburg
    Inventors: V. Prasad Shastri, Aurelien Forget
  • Patent number: 10961549
    Abstract: Methods of identifying genes conferring ethanol tolerance in yeasts, genes that confer ethanol tolerance, and mutant strains used to identify such genes are described. A gene herein designated HpETT1 was isolated from the yeast Hansenula polymorpha. Expression of HpETT1 in an ethanol sensitive mutant H. polymorpha strain designated 7E complimented ethanol sensitivity of the mutant. When multiple copies of the HpETT1 were integrated into the genome and overexpressed, the transformed strain demonstrated approximately 10-fold greater resistance to ethanol and resistance to the protein misfolding agent AZC. Expression of HpETT1 also increased ethanol tolerance in Saccharomyces cerevisiae. HpEtt1 has 39% sequence identity to a previously identified protein from S. cerevisiae denoted MPE1, however, the MPE1 gene does not confer ethanol resistance to the 7E mutant.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: March 30, 2021
    Assignee: ARCHER DANIELS MIDLAND COMPANY
    Inventors: Charles Abbas, Andriy Sibirny, Andriy Voronovsky, Olena Ishchuk
  • Patent number: 10960399
    Abstract: Cartridge-based thermocyclers can include cartridges that are configured to move a fluid between distinct chambers. In some cases, the cartridge-based thermocyclers can be used for thermocycling a sample fluid comprising a deoxyribonucleic acid (DNA) target to perform polymerase chain reaction (PCR). Individual chambers can be heated, cooled, and/or compressed to mix fluid within the chamber or to propel fluid in the chamber into another chamber. The cartridges can have a laminate construction. The cartridges can be configured to enable multiplexed thermocycling and/or detection.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 30, 2021
    Assignee: Visby Medical, Inc.
    Inventors: Hamilton R. Tang, Adam De La Zerda, Kenneth I. Li, Kevin M. Limtao, Alan D. Baldwin, Gregory C. Loney
  • Patent number: 10961571
    Abstract: This specification generally relates to non-radioactive methods of detecting nucleic acid polymerase activity and methods of detecting compounds that modulate nucleic acid polymerase activity. The activity may be measured in real-time using a real-time PCR instrument.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: March 30, 2021
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Lei Xi, Keith P. Bjornson, Stephen P. Hendricks
  • Patent number: 10955407
    Abstract: The invention relates to methods for predicting the in vivo toxicity of oligonucleotides, such as antisense oligonucleotides using in vitro cell based assays based on gymnotically administering oligonucleotides to primary mammalian hepatocytes and subsequently measuring the levels of toxicity biomarkers such as the release of LDH into the cell culture media and/or intracellular ATP.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: March 23, 2021
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Franziska Boess, Sabine Sewing, Annie Moisan, Adrian B. Roth, Cristina Bertinetti-Lapatki
  • Patent number: 10954542
    Abstract: This disclosure provides, among other things, a method for making a cDNA library. In some embodiments the method may comprise adding a polyA tail to the longer RNA fragments but not the shorter RNA fragments in a sample by incubating the population of RNA fragments with a polyA polymerase, wherein the reaction conditions used preferentially tail only the longer fragments but not the shorter fragments.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: March 23, 2021
    Assignee: BIOO SCIENTIFIC CORPORATION
    Inventor: Kevin Allen
  • Patent number: 10954563
    Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 23, 2021
    Assignees: UNIVERSITAT DE BARCELONA, HOSPITAL CLINIC DE BARCELONA, INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUSUST PI 1 -SUNYER, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER)
    Inventors: Sergi Mas Herrero, Patricia Gassó Astorga, Cristina Malagelada Grau, Miquel Bernardo Arroyo, Amalia Lafuente Flo
  • Patent number: 10947588
    Abstract: The present invention relates to the technical field of nucleic acid amplification using a Polymerase Chain Reaction (PCR). Specifically, the present invention relates to Polymerase Chain Reaction (PCR) primers and Polymerase Chain Reaction (PCR) nucleic acid amplification mixture and the use thereof in (quantitative) Polymerase Chain Reactions (PCR).
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 16, 2021
    Assignee: MULTIPLICOM N.V.
    Inventor: Jurgen Del Favero
  • Patent number: 10950327
    Abstract: The present tools and methods for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject. These tools and methods relates to a genotype and neurophenotype topography-based approach for analyzing brain neuroimaging and gene expression maps to identify drug targets associated with neurobehavioral phenotypes and, conversely, neurobehavioral phenotypes associated with potential drug targets, to develop rational design and application of pharmacological therapeutics for brain disorders, and to provide methods and tools for treatment of subjects in need of neurological therapy.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: March 16, 2021
    Assignees: BlackThorn Therapeutics, Inc., Yale University
    Inventors: John D. Murray, Alan Anticevic, William J. Martin
  • Patent number: 10942165
    Abstract: A method for increasing the number of analyte/assay combinations in a single chip or cartridge of an in vitro diagnostic system may include: prioritizing a set of analyte/assay combinations based on characteristics of each analyte in the set of analyte/assay combinations, wherein the characteristics comprise one selected from the group consisting of a prevalence of each analyte, a clinical relevance of each analyte, a clinical actionability of each analyte, a patient benefit, a cost savings, and any combination thereof; deriving an analyte/analyte interactivity for two or more analytes in the set of analyte/assay combinations; designing a plurality of candidate panel layouts based on panel layout rules, the prioritization of the set of analyte/assay combinations, and the analyte/analyte interactivity, wherein the panel layout comprises one or more chips each comprising a chamber with two or more analytes; and validating the plurality of candidate panel layouts to produce panel layout solutions.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 9, 2021
    Assignee: DNAe Group Holdings Ltd
    Inventors: Zahid Ansari, Peter Charles Howard, Francois Paillier, Christopher Maurice Neville Tofts
  • Patent number: 10935541
    Abstract: Disclosed herein are devices comprising one or more cantilevers comprising one or more neuromuscular junctions formed by a co-culture of myotubes and motoneurons. Disclosed herein are methods of using the disclosed devices comprising one or more cantilevers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 2, 2021
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: James Hickman, Alexander Smith, Christopher Long, Kristen Pirozzi
  • Patent number: 10934587
    Abstract: The present invention relates to compositions, kits, and methods for molecular profiling and cancer diagnostics, including but not limited to genomic DNA markers associated with cancer. In particular, the present invention provides molecular profiles associated with thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 2, 2021
    Assignee: Veracyte, Inc.
    Inventors: Giulia Kennedy, Bonnie H. Anderson, Darya I. Chudova, Eric T. Wang, Hui Wang, Moraima Pagan, Nusrat Rabbee, Jonathan I. Wilde
  • Patent number: 10934539
    Abstract: Methods of isolating nucleic acids comprising DNA from biological material are disclosed. The methods comprise a lysis step using an aqueous composition which comprises lithium at a concentration of 0.05 to 1.0M, a chelating agent, and a surfactant to produce a lysed composition. The lysed composition is treated with a solid support that is capable of immobilising DNA in the presence of a dissolved chaotropic agent at a concentration of 0.05 to 2M and 25% to 60% by volume of a C1-3 alkanol. The support is then washed with a first wash solution containing lithium dissolved in a C1-3 alkanol. Subsequently, the support is washed with a liquid comprising at least 80% by volume of a C1-3 alkanol. The nucleic acid comprising DNA is then eluted from the support.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: March 2, 2021
    Assignee: RevoluGen Limited
    Inventors: Stephen John Minter, Georgios Patsos
  • Patent number: 10927379
    Abstract: Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 23, 2021
    Assignee: BIO-PATH HOLDINGS, INC.
    Inventor: Ana Tari Ashizawa
  • Patent number: 10907193
    Abstract: A device, method, and system for the detection of ribosome inactivating protein activity, including the ricin toxin, in a sample. According to one embodiment, the ribosome inactivating protein in the sample removes an adenine from a labeled DNA substrate to create an abasic site. An AP lyase can then cleave the DNA substrate at the abasic site, allowing the fluorophore located at or near one end of the DNA substrate and the quencher at or near the other end of the DNA substrate to spatially separate. Once the fluorophore and the quencher are sufficiently separated, the fluorophore will emit a fluorescence signal. Increasing fluorescence, indicating ribosome inactivating protein activity, will be monitored in real time using a detection system.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 2, 2021
    Assignee: ACUMEN DETECTION, LLC
    Inventors: Huda Sirageldin Suliman, Stacey Ann Massulik, Frances Louise Stites, Timothy Francis Moshier, Kenton Arthur Doctor, Jeffrey Harold Mills, Lisa Helen Chamberlin
  • Patent number: 10898462
    Abstract: The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: January 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo
  • Patent number: 10900044
    Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 26, 2021
    Assignee: ADVAXIS, INC.
    Inventors: Robert Petit, Michael F. Princiotta
  • Patent number: 10900088
    Abstract: Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: January 26, 2021
    Assignee: The Johns Hopkins University
    Inventors: Bert Volgelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Rebecca J. Leary
  • Patent number: 10889814
    Abstract: Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: January 12, 2021
    Inventors: Yuzhuo Wang, Stephen Yiu Chuen Choi
  • Patent number: 10889863
    Abstract: FRET-based analytes detection and related methods and systems are described where a pair of FRET labeled primers and/or oligonucleotides are used that are specific for target sequences located at a distance up to four time the Förster distance of the FRET chromophores presented on the FRET labeled primers and/or oligonucleotides one with respect to the other in one or more polynucleotide analyte; in particular the pair of FRET labeled primers and/or oligonucleotides is combined with a sample and subjected to one or more polynucleotide amplification reactions before measuring FRET signals from at least one FRET chromophore.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: January 12, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Emil P. Kartalov, Aditya Rajagopal, Axel Scherer, Mark D. Goldberg
  • Patent number: 10881677
    Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: January 5, 2021
    Assignee: Agency for Science, Technology and Research
    Inventors: Qiang Yu, Zhen Ning Wee
  • Patent number: 10883100
    Abstract: The invention provides columns (including pipette tip columns) and automated methods for the purification of nucleic acids including plasmids. Nucleic acids can be purified from unclarified, clarified or partially-clarified cell lysates that contain cell debris. The columns typically include a bed of medium positioned above a bottom frit and with an optional top frit. Plasmid preparation scales include miniprep, midiprep, maxiprep, megaprep and gigaprep.
    Type: Grant
    Filed: April 9, 2017
    Date of Patent: January 5, 2021
    Assignee: PhyNexus, Inc
    Inventors: Chris Suh, Carrie Loan Kim Huynh, Lee Hoang, Douglas T. Gjerde, Jonathan Michael Grambow
  • Patent number: 10876164
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 29, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Patent number: 10874711
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that masks or otherwise blocks phosphatidylserine on the pathogen cell surface.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 29, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Francis Gerard Blankenberg
  • Patent number: 10876117
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 29, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10870885
    Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences dendritic cell (DC) response(s), for example, dendritic cell maturation, dendritic cell antiviral response(s) and/or dendritic cell inflammatory response(s), as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences dendritic cell response(s) in a variety of therapeutic and/or diagnostic indications.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: December 22, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Aviv Regev, Alexander K. Shalek, Rahul Satija, Hongkun Park
  • Patent number: 10870851
    Abstract: Aspects of the present disclosure include RNAs that confer a mortal phenotype and nucleic acids encoding same. Liposomes, recombinant cells, and pharmaceutical compositions that include the RNAs or nucleic acids encoding same are also provided. Further provided are methods involving quantifying MORT RNAs and/or determining the methylation status of the MORT promoter, as well as methods that employ the RNAs or nucleic acids encoding same.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 22, 2020
    Assignees: The Regents of the University of California, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Martha R. Stampfer, James C. Garbe, Lukas Vrba, Bernard W. Futscher
  • Patent number: 10865383
    Abstract: Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: December 15, 2020
    Assignee: LINEAGE CELL THERAPEUTICS, INC.
    Inventors: Michael West, Hal Sternberg
  • Patent number: 10858688
    Abstract: An observation method of a sample containing a target substance, the observation method including an imaging step in which a step of obtaining a speckle image including, as a speckle, light emitted from a luminescent substance in which a medium is brought into contact with the sample is performed a plurality of times so as to obtain a plurality of speckle images, the medium containing a probe that contains the luminescent substance emitting light and that repeatedly binds to and dissociates from the target substance directly and specifically, and an observation image generation step of generating an observation image of the target substance in the sample from the plurality of speckle images, wherein a half-life of a probe-target complex formed by binding between the probe and the target substance is equal to or more than 10 milliseconds and equal to or less than 3 seconds.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 8, 2020
    Assignee: KYOTO UNIVERSITY
    Inventors: Tai Kiuchi, Naoki Watanabe
  • Patent number: 10858761
    Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
    Type: Grant
    Filed: February 22, 2020
    Date of Patent: December 8, 2020
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held
  • Patent number: 10849965
    Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: December 1, 2020
    Assignee: The Regents of the University of California
    Inventors: Hideho Okada, Yafei Hou
  • Patent number: 10842728
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 10831811
    Abstract: A system and method for facilitating machine interpretation of potentially ambiguous input, such as natural language. An example method includes constructing an ontology based on a database schema, wherein the ontology includes one or more indications of relationship strengths characterizing two or more entities of the ontology; collecting context information pertaining to a relevant domain; receiving the potentially ambiguous input; employing the input and the ontology to estimate a meaning of the input using the context information, the one or more indications of relationship strength, and an estimation of a probability that one or more portions of the natural language input refer to a particular entity.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: November 10, 2020
    Assignee: Oracle International Corporation
    Inventors: William Kraus, Jeremy Ashley, Jatin Thaker
  • Patent number: 10823719
    Abstract: The invention relates to methods and devices for quantitative determination of bacteria.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: November 3, 2020
    Assignee: Swiss Analyze Bacteria AG
    Inventors: Dieter Ebert, Mathias Reichl, Werner Lubitz
  • Patent number: 10822369
    Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: November 3, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Xue-hai Liang, Wen Shen
  • Patent number: 10820581
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Vera Voronina, Cagan Gurer
  • Patent number: 10825353
    Abstract: Methods and devices can enhance language processing in an autism spectrum disorder (ASD) individual through auditory manipulation of an auditory stream. The auditory stream is received and includes an acoustic stimulus perceptually representing an object. An acoustic manipulation parameter for a predetermined acoustic detail characteristic is selected. The predetermined acoustic detail characteristic is associated with the ASD individual and is based on a measured language processing capability of the ASD individual. The auditory stream is modified based on the selected parameter, to reduce the predetermined acoustic detail characteristic while preserving a lexicality of the stimulus, such that the reduced acoustic detail characteristic enhances perception of the object by the ASD individual even when the stimulus includes two or more acoustically distinct stimuli each perceptually representing the object. The modified auditory stream is output to the ASD individual via at least one loudspeaker.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: November 3, 2020
    Assignees: The Children's Hospital of Philadelphia, The Trustees of the University of Pennsylvania
    Inventors: Timothy Roberts, David Embick
  • Patent number: 10815478
    Abstract: Presented herein are methods and compositions for tagmentation of nucleic acids. The methods are useful for generating tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: October 27, 2020
    Assignee: Illumina, Inc.
    Inventors: Christian Gloeckner, Amirali Kia, Molly He, Trina Faye Osothprarop, Frank J. Steemers, Kevin L. Gunderson, Sasan Amini, Jerome Jendrisak
  • Patent number: 10806748
    Abstract: In some aspects, the invention relates to methods for determining the proportion of intact, hypermutated, deleted, and/or defective proviruses in a sample of nucleic acids, e.g., a sample obtained from a subject. The subject may be a human subject. The virus may be HIV.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 20, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Katherine Bruner, Robert Siliciano
  • Patent number: 10799475
    Abstract: Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 13, 2020
    Assignee: Northwestern University
    Inventors: Irina Budunova, Alexander Yemelyanov
  • Patent number: 10793834
    Abstract: Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins. The live-attenuated viruses display unaltered replication in avian hosts for propagation, but attenuated replication in mammalian hosts, when compared to the replication of the parental virus. The live-attenuated viruses in a form of improved vaccines can be used to elicit protective immune responses.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 6, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Lit Man Poon, Lok Yan Fan
  • Patent number: 10793910
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 6, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Matthew J. McGinniss, Arlene M Buller, Franklin Quan, Mei Peng, Weimin Sun
  • Patent number: 10793857
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: October 6, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • Patent number: 10793914
    Abstract: Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 6, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Johan Karl Olov Skog, Leonora Balaj, Mikkel Noerholm, Xandra O. Breakefield
  • Patent number: 10796005
    Abstract: Provided is a method of application security vulnerability evaluation based on tree boosting and a readable medium and an apparatus for performing the same. The method of application security vulnerability evaluation based on tree boosting includes the step of generating an API classifier which classifies an input API as benign or malicious using a tree boosting-based algorithm, the step of calculating security vulnerability score of API using the API classifier, and the step of classifying a target application as a malicious application or a benign application according to the security vulnerability score of API used in the target application.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: October 6, 2020
    Assignee: Foundation of Soongsil University-Industry Cooperation
    Inventors: Jeong Hyun Yi, Kichang Kim
  • Patent number: 10786686
    Abstract: The present invention relates to a method for preventing cancerization of normal cells due to low-dose irradiation. The method enables effective prevention of cancerization of normal cells by means of low-dose radiation which is innocuous to a subject.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 29, 2020
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Seonyoung Nam, Kwang Hee Yang, Su-Jae Lee, Rae-Kwon Kim
  • Patent number: 10772927
    Abstract: The present invention relates to the use of a casein hydrolysate as an antiviral agent for the treatment of opportunistic virus infections, especially herpesvirus and human papillomavirus. This casein hydrolysate has an application in both the therapeutic treatment of established symptoms and the prevention of the infection or the reactivation of a latent infection by an opportunistic virus. The casein hydrolysate of the present invention is effective for the prevention of opportunistic virus infections in individuals with weakened immune system.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: September 15, 2020
    Assignee: NTD Labs, S.L.
    Inventors: Pere Adell Winkler, Guillermo Lopez Zarco
  • Patent number: 10774375
    Abstract: Provided herein are products and processes for the quantitation of mitochondrial nucleic acid in a sample from a subject. In certain aspects are multiplex methods for determining dosage of mitochondrial nucleic acid relative to genomic nucleic acid for a sample from a subject including amplifying sets of mitochondrial polynucleotides and genomic polynucleotides from nucleic acid for a sample under amplification conditions. In certain aspects are multiplex methods for determining dosage of mitochondrial nucleic acid relative to genomic nucleic acid for a sample from a subject including amplifying sets of mitochondrial polynucleotides and amplifying sets of nuclear polynucleotides from nucleic acid for a sample under amplification conditions.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 15, 2020
    Assignee: Agena Bioscience, Inc.
    Inventor: Anders Olof Herman Nygren
  • Patent number: 10768185
    Abstract: Disclosed herein are antibodies capable of specifically binding to tenofovir (TFV), a key small molecule drug for both the treatment and prevention of HIV, and a competitive lateral flow assay that uses these antibodies to monitor urine samples for the presence of the drug. The assay can be deployed as a point-of-care device for adherence monitoring.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: September 8, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Catherine M. Klapperich, George Woodman Pratt, IV, Andy Fan
  • Patent number: 10761053
    Abstract: Embodiments described herein relate generally to compositions that include a synthetic redox-active receptor, and in particular to compositions that include a boronic acid based synthetic redox-active receptor which can electrochemically sense a target analyte in a sample solution. In some embodiments, a synthetic redox-active receptor can have a composition of formula I: wherein the variables L, L?, R, R?, n and X? are described herein.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: September 1, 2020
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventor: Jeff T. Suri